- Format
- Oral disintegrating tablet
- Reference price
- $159 shown; not treated as a verified renewal
- Quantity
- Confirm strength, tablet count and supply period
An oral tablet deserves its own entry
System Labs presents Oral Compounded Sermorelin on a separate product page from its injection. The route is an oral disintegrating tablet, which we identify separately from troches, films and injectable preparations elsewhere in this guide. Similar ingredient names do not establish identical formulation, absorption or clinical performance across those delivery systems.
The checked page displayed $79 for the first month alongside a $159 reference figure. We retain the introductory amount but do not label the reference as a confirmed automatic renewal. The selected plan's order summary should state the full initial charge, billing frequency and subsequent amount before the offer is compared with another provider's ongoing price.
Confirm the tablet supply and care inclusions
Ask for the strength, tablet count and actual supply period attached to the chosen prescription. The convenience of an oral format does not resolve those purchasing details. A quoted monthly period may describe the service or payment cycle while leaving the exact medication quantity to the clinical assessment and dispensing process.
System Labs describes online prescribing and fulfillment when treatment is appropriate. Clarify whether the displayed offer covers all required consultations, shipping and follow-up, and whether laboratory work is billed separately. We have not ordered the tablets or reviewed a patient-specific invoice, so the visible starting figure should not be treated as a verified all-inclusive cost of care.
Read the evidence for this route
An explanation of growth-hormone signaling is not a clinical trial of the finished oral preparation. Findings from injected sermorelin cannot automatically prove equivalent effects from an oral disintegrating tablet. Ask the prescriber which human studies support the proposed formulation and purpose, and how the uncertainty affects the decision to use it.
The product is compounded and is not FDA-approved. Historical approval of a different sermorelin product does not change that status. This review makes no claim that an oral route is safer, more effective or clinically equivalent to an injection; it identifies a distinct offer whose evidence and monitoring requirements need their own discussion.
Handle subscriptions and product questions separately
The provider's terms distinguish an early cancellation before transfer to the partner pharmacy from an order that has already been processed or shipped. They also describe a separate seven-day reporting process for incorrect or damaged orders. Obtain the actual cancellation deadline for the chosen refill cycle rather than assuming the first-month promotion creates a risk-free trial.
The dispensing pharmacy should supply handling and beyond-use information for the tablets actually sent. Keep its contact details alongside the clinician's support pathway, because a shipment problem and a medical question may need different responses. A sound comparison of this oral offer combines the selected payment agreement, tablet specification and route-specific evidence instead of letting a low first-month headline answer all three questions.
Sources & further reading
Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.